Abel Hall LLC lifted its position in Astrazeneca Plc (NYSE:AZN – Free Report) by 108.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,276 shares of the company’s stock after purchasing an additional 3,270 shares during the period. Abel Hall LLC’s holdings in Astrazeneca were worth $1,013,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of AZN. Professional Advisory Services Inc. bought a new position in shares of Astrazeneca during the 2nd quarter worth $30,241,000. Wealthcare Advisory Partners LLC purchased a new position in shares of Astrazeneca during the second quarter valued at $2,296,000. Andra AP fonden increased its stake in shares of Astrazeneca by 122.9% during the second quarter. Andra AP fonden now owns 526,714 shares of the company’s stock valued at $99,876,000 after buying an additional 290,412 shares during the period. Westport Asset Management Inc. bought a new stake in shares of Astrazeneca in the second quarter valued at about $1,422,000. Finally, Madison Asset Management LLC bought a new stake in shares of Astrazeneca in the second quarter valued at about $4,041,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.
Analyst Upgrades and Downgrades
AZN has been the subject of a number of research reports. Zacks Research raised shares of Astrazeneca from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. Bank of America reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Finally, Weiss Ratings cut shares of Astrazeneca from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, July 28th. Fifteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Astrazeneca has an average rating of “Moderate Buy” and an average target price of $206.67.
Astrazeneca Stock Down 0.8%
Shares of NYSE:AZN traded down $1.38 on Monday, reaching $164.03. The company had a trading volume of 2,322,055 shares, compared to its average volume of 2,812,117. The firm has a market capitalization of $254.40 billion, a PE ratio of 24.52, a PEG ratio of 1.40 and a beta of 0.27. The company has a current ratio of 0.89, a quick ratio of 0.67 and a debt-to-equity ratio of 0.47. Astrazeneca Plc has a 52-week low of $153.41 and a 52-week high of $212.71. The firm’s 50 day simple moving average is $162.16 and its 200-day simple moving average is $175.96.
Astrazeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings data on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%. The firm had revenue of $15.38 billion during the quarter, compared to analysts’ expectations of $15.44 billion. During the same period in the prior year, the business posted $2.17 EPS. The firm’s quarterly revenue was up 6.4% on a year-over-year basis. As a group, analysts expect that Astrazeneca Plc will post 9.38 earnings per share for the current fiscal year.
Astrazeneca Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.
AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Featured Stories
- Five stocks we like better than Astrazeneca
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
